Plant Name: Gossypium herbaceum
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0055114; oxidation-reduction process | 2.953E-09 | 6.429E-05 | AKR1B1, ALDH1A1, ALOX12, ALOX15, CYP2A6, CYP2C19, GAA, HSD17B10, KDM4E, LDHA, LDHB |
| BP | GO:0009987; cellular process | GO:0008630; intrinsic apoptotic signaling pathway in response to DNA damage | 1.879E-08 | 9.871E-05 | BCL2, BCL2L1, MCL1, POLB, TP53 |
| MF | GO:0005488; binding | GO:0051434; BH3 domain binding | 1.683E-08 | 9.871E-05 | BCL2, BCL2L1, MCL1 |
| BP | GO:0008152; metabolic process | GO:0006089; lactate metabolic process | 2.763E-07 | 7.520E-04 | HIF1A, LDHA, LDHB |
| BP | GO:0008152; metabolic process | GO:0019369; arachidonic acid metabolic process | 5.560E-07 | 1.211E-03 | ALOX12, ALOX15, CYP2A6, CYP2C19 |
| BP | GO:0050896; response to stimulus | GO:0010332; response to gamma radiation | 5.560E-07 | 1.211E-03 | BCL2, BCL2L1, POLB, TP53 |
| BP | GO:0009987; cellular process | GO:2001244; positive regulation of intrinsic apoptotic signaling pathway | 6.447E-07 | 1.276E-03 | BCL2, BCL2L1, MCL1, TP53 |
| BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 1.480E-06 | 1.696E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 1.480E-06 | 1.696E-03 | ALOX12, ALOX15 |
| BP | GO:0032502; developmental process | GO:0048856; anatomical structure development | 4.579E-06 | 3.835E-03 | AKR1B1, ALOX15, BCL2, BCL2L1, ESR1, GAA, HIF1A, LDHA, LMNA, MCL1, POLB, THPO, TP53, TSHR |
| BP | GO:0009987; cellular process | GO:2001243; negative regulation of intrinsic apoptotic signaling pathway | 5.410E-06 | 3.835E-03 | BCL2, BCL2L1, HIF1A, MCL1 |
| BP | GO:0009987; cellular process | GO:0006284; base-excision repair | 6.693E-06 | 3.835E-03 | MPG, POLB, TP53 |
| MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 4.435E-06 | 3.835E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 4.435E-06 | 3.835E-03 | ALOX12, ALOX15 |
| BP | GO:0008283; cell proliferation | GO:0008284; positive regulation of cell proliferation | 7.304E-06 | 3.838E-03 | AKR1B1, ALOX12, BCL2, BCL2L1, ESR1, HIF1A, THPO, TSHR |
| BP | GO:0050896; response to stimulus | GO:0009636; response to toxic substance | 7.668E-06 | 3.838E-03 | AKR1B1, BCL2, BCL2L1, LDHA, POLB, TP53 |
| BP | GO:0009987; cellular process | GO:0071456; cellular response to hypoxia | 7.756E-06 | 3.838E-03 | BCL2, HIF1A, LMNA, TP53 |
| BP | GO:0009987; cellular process | GO:2001240; negative regulation of extrinsic apoptotic signaling pathway in absence of ligand | 9.833E-06 | 4.556E-03 | BCL2, BCL2L1, MCL1 |
| BP | GO:0008152; metabolic process | GO:0051122; hepoxilin biosynthetic process | 1.476E-05 | 5.448E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0004459; L-lactate dehydrogenase activity | 1.476E-05 | 5.448E-03 | LDHA, LDHB |
| BP | GO:0050896; response to stimulus | GO:0010035; response to inorganic substance | 1.691E-05 | 5.911E-03 | AKR1B1, ALOX15, BCL2, HIF1A, LDHA, TP53 |
| BP | GO:0050896; response to stimulus | GO:0034097; response to cytokine | 2.050E-05 | 6.663E-03 | ALOX15, BCL2, BCL2L1, HIF1A, MCL1, TP53 |
| BP | GO:0065007; biological regulation | GO:0042592; homeostatic process | 2.103E-05 | 6.734E-03 | AKR1B1, ALOX12, BCL2, ESR1, GAA, HIF1A, MCL1, POLB, TP53 |
| CC | GO:0032991; macromolecular complex | GO:0097136; Bcl-2 family protein complex | 2.213E-05 | 6.773E-03 | BCL2L1, MCL1 |
| BP | GO:0008152; metabolic process | GO:0019748; secondary metabolic process | 3.375E-05 | 9.422E-03 | AKR1B1, BCL2, CYP2A6 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 7.071E-07 | 3.147E-05 | LDHB; CYP2A6; LDHA; GAA; ALOX15; ALDH1A1; AKR1B1; ALOX12; CYP2C19; HSD17B10 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 5.974E-07 | 3.147E-05 | LMNA; BCL2; TP53; BCL2L1; MCL1 |
| hsa04630 | Jak-STAT signaling pathway_Homo sapiens_hsa04630 | 3.522E-05 | 7.837E-04 | THPO; BCL2; BCL2L1; MCL1 |
| hsa05014 | Amyotrophic lateral sclerosis (ALS)_Homo sapiens_hsa05014 | 3.044E-05 | 7.837E-04 | BCL2; TP53; BCL2L1 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 5.481E-05 | 9.757E-04 | ALOX15; ALOX12; CYP2C19 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 6.916E-05 | 1.026E-03 | LDHA; TP53; HIF1A |
| hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 1.455E-04 | 1.850E-03 | BCL2; TP53; BCL2L1 |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 2.482E-04 | 2.761E-03 | LDHA; BCL2; HIF1A |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 3.176E-04 | 3.140E-03 | ALOX15; ALOX12; CYP2C19 |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 3.702E-04 | 3.294E-03 | TP53; ESR1; HIF1A |
| hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 6.736E-04 | 4.226E-03 | BCL2; TP53; BCL2L1; MCL1 |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 1.186E-03 | 6.210E-03 | BCL2; HIF1A; TP53; BCL2L1 |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 1.782E-03 | 8.347E-03 | TP53; HIF1A; ESR1 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 5.493E-04 | 4.226E-03 | ALOX15; CYP2C19 |
| hsa00640 | Propanoate metabolism_Homo sapiens_hsa00640 | 6.696E-04 | 4.226E-03 | LDHB; LDHA |
| hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 5.881E-04 | 4.226E-03 | GAA; AKR1B1 |
| hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 2.497E-03 | 1.111E-02 | BCL2; TP53 |
| hsa05166 | HTLV-I infection_Homo sapiens_hsa05166 | 3.515E-03 | 1.159E-02 | POLB; TP53; BCL2L1 |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 2.825E-03 | 1.126E-02 | TP53; BCL2L1 |
| hsa00620 | Pyruvate metabolism_Homo sapiens_hsa00620 | 1.047E-03 | 5.823E-03 | LDHB; LDHA |
| hsa00010 | Glycolysis / Gluconeogenesis_Homo sapiens_hsa00010 | 2.909E-03 | 1.126E-02 | LDHB; LDHA |
| hsa00270 | Cysteine and methionine metabolism_Homo sapiens_hsa00270 | 1.324E-03 | 6.546E-03 | LDHB; LDHA |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 2.741E-03 | 1.126E-02 | CYP2A6; ALDH1A1 |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 5.208E-03 | 1.545E-02 | BCL2; TP53; MCL1 |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 3.443E-03 | 1.159E-02 | TP53; BCL2L1 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 3.083E-03 | 1.143E-02 | CYP2A6; CYP2C19 |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 5.071E-03 | 1.545E-02 | BCL2; TP53 |
| hsa03410 | Base excision repair_Homo sapiens_hsa03410 | 7.123E-04 | 4.226E-03 | POLB; MPG |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 3.260E-03 | 1.159E-02 | SLCO1B1; SLCO1B3 |
| hsa04922 | Glucagon signaling pathway_Homo sapiens_hsa04922 | 6.482E-03 | 1.748E-02 | LDHB; LDHA |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 4.322E-03 | 1.374E-02 | CYP2A6; CYP2C19 |
| hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 8.752E-03 | 2.235E-02 | BCL2; BCL2L1 |
| hsa04064 | NF-kappa B signaling pathway_Homo sapiens_hsa04064 | 5.524E-03 | 1.586E-02 | BCL2; BCL2L1 |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 9.039E-03 | 2.235E-02 | BCL2; TP53 |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 1.315E-02 | 3.163E-02 | BCL2; TP53 |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 9.039E-03 | 2.235E-02 | BCL2; TP53 |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 1.952E-02 | 4.573E-02 | TP53; BCL2L1 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 5.986E-03 | 1.665E-02 | CYP2A6 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; ESR1 |
| N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1 |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1 |
| H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1 |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | ESR1 |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | ESR1; ESR1 |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53 |
| NA: NA | Lymphoid malignancies | NA | BCL2L1 |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | BCL2; HIF1A |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | ESR1 |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53 |
| C00-D49: Neoplasms | Leukemia | C90-C95 | BCL2; ESR1 |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | BCL2L1; HIF1A; TP53 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1 |
| NA: NA | Gonorrheal vaginitis | NA | ESR1 |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1 |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| C00-D49: Neoplasms | Prostate cancer | C61 | BCL2; ESR1 |
| N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| C00-D49: Neoplasms | Relapsed or refractory chronic lymphocytic leukemia | NA | BCL2L1 |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| NA: NA | Menopausal disorder | NA | ESR1 |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1 |
| N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1 |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | ESR1 |
| C00-D49: Neoplasms | Advanced melanoma | C43 | BCL2 |
| C00-D49: Neoplasms | Advanced small cell lung cancer | NA | BCL2L1 |
| Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1 |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | AKR1B1 |
| C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | BCL2 |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | ESR1 |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | AKR1B1 |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1 |
| C00-D49: Neoplasms | Breast cancer | C50 | BCL2; ESR1; ESR1 |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1 |
| C00-D49: Neoplasms | Cancer | C00-C96 | BCL2; BCL2; BCL2L1; HIF1A; TP53; ESR1; ESR1; MCL1 |
| G00-G99: Diseases of the nervous system G00-G99 | Amyotrophic lateral sclerosis | G12.2 | BCL2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ESR1 |
| C00-D49: Neoplasms | Multiple myeloma | C90 | BCL2 |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ESR1; ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | BCL2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1 |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53; AKR1B1 |
| Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
| N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1 |
| NA: NA | Postmenopausal disorder | NA | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | ESR1 |